COST EFFECTIVENESS OF OFATUMUMAB IN COMPARISON WITH OTHER DISEASE MODIFYING THERAPIES AND BEST SUPPORTIVE CARE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA

被引：0
|
作者：
Mouallif, S. [1 ]
Thomas, K. [2 ]
Adlard, N. E. [3 ]
Cooney, P. [4 ]
Blanchette, F. [1 ]
Patel, B. P.
Baharnoori, M. [5 ]
Bhan, V [6 ]
Clift, F. [7 ]
Grima, D.
机构：
[1] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
[2] Eversana, Burlington, ON, Canada
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Ireland Ltd, Dublin, Ireland
[5] Queens Univ, Dept Med, Kingston, ON, Canada
[6] Univ British Columbia, Vancouver, BC, Canada
[7] Mem Univ Newfoundland, St John, NF, Canada
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA148
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [1] Cost effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Mouallif, Soukaina
    Thomas, Kim
    Adlard, Nicholas
    Cooney, Philip
    Blanchette, Francois
    Patel, Barkha
    Baharnoori, Moogeh
    Bhan, Virender
    Clift, Fraser
    Grima, Daniel
    [J]. NEUROLOGY, 2022, 98 (18)
  • [2] Cost-effectiveness of ofatumumab in comparison with other disease modifying therapies and best supportive care for the treatment of relapsing-remitting multiple sclerosis in Canada
    Mouallif, S.
    Thomas, K.
    Adlard, N.
    Cooney, P.
    Blanchette, F.
    Patel, B.
    Baharnoori, M.
    Bhan, V.
    Clift, F.
    Grima, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 311 - 311
  • [3] COST-CONSEQUENCE ANALYSIS OF OFATUMUMAB IN COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES AND BEST SUPPORTIVE CARE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA
    Farhane, F.
    Bhan, V
    Clift, F.
    Baharnoori, M.
    Thomas, K.
    Patel, B. P.
    Blanchette, F.
    Adlard, N. E.
    Vudumula, U.
    Gudala, K.
    Dutta, N.
    Grima, D.
    Mouallif, S.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S55 - S56
  • [4] THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Bozkaya, D.
    Livingston, T. P.
    Migliaccio-Walle, K.
    Mehta, S.
    Odom, T.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : S283 - S283
  • [5] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Moogeh Baharnoori
    Virender Bhan
    Fraser Clift
    Kimberly Thomas
    Soukaïna Mouallif
    Nicholas Adlard
    Philip Cooney
    François Blanchette
    Barkha P. Patel
    Daniel Grima
    [J]. PharmacoEconomics - Open, 2022, 6 : 859 - 870
  • [6] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Baharnoori, Moogeh
    Bhan, Virender
    Clift, Fraser
    Thomas, Kimberly
    Mouallif, Soukaina
    Adlard, Nicholas
    Cooney, Philip
    Blanchette, Francois
    Patel, Barkha P.
    Grima, Daniel
    [J]. PHARMACOECONOMICS-OPEN, 2022, 6 (06) : 859 - 870
  • [7] The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
    Bozkaya, Duygu
    Livingston, Terrie
    Migliaccio-Walle, Kristen
    Odom, Tanner
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 297 - 302
  • [8] Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
    Bhan, Virender
    Clift, Fraser
    Baharnoori, Moogeh
    Thomas, Kimberly
    Patel, Barkha P.
    Blanchette, Francois
    Adlard, Nicholas
    Vudumula, Umakanth
    Gudala, Kapil
    Dutta, Nikkita
    Grima, Daniel
    Mouallif, Soukaina
    Farhane, Fatine
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (09)
  • [9] COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE
    Petropoulos, A.
    Cooney, P.
    Patidar, M.
    Gudala, K.
    Tiwari, S.
    Brennan, R.
    Kapsogeorgiou, K.
    Cheilas, G.
    Banhazi, J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S80 - S81
  • [10] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
12345